Company Perrigo Company plc TEL AVIV STOCK EXCHANGE
Stocks
PRGO
IE00BGH1M568
Pharmaceuticals
Business description: Perrigo Company plc
Number of employees: 8,100
Sales by Activity: Perrigo Company plc
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
Consumer Self-Care Americas (Csca) | 2.69B | 2.93B | 2.96B | 2.69B | 2.59B |
Consumer Self-Care International(Csci) | 1.45B | 1.53B | 1.69B | 1.68B | 1.67B |
Geographical breakdown of sales: Perrigo Company plc
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
United States (U.S.) | 2.57B | 2.87B | 2.92B | 2.65B | 2.54B |
Europe (Excl. Ireland) | 1.37B | 1.44B | 1.58B | 1.56B | 1.57B |
All Other Countries | 180M | 107M | 116M | 120M | 96.7M |
Ireland | 23.7M | 29.3M | 40.8M | 39.6M | 42.1M |
Executive Committee: Perrigo Company plc
| Manager | Title | Age | Since |
|---|---|---|---|
Albert Manzone
CEO | Chief Executive Officer | 63 | 2026-06-06 |
Eduardo Bezerra
DFI | Director of Finance/CFO | 51 | 2022-05-15 |
Matt Winterman
COO | Chief Operating Officer | - | 2025-06-22 |
Abbie Lennox
CTO | Chief Tech/Sci/R&D Officer | 45 | 2025-01-05 |
Bradley Joseph
IRC | Investor Relations Contact | - | 2011-06-30 |
Composition of the Board of Directors: Perrigo Company plc
| Director | Title | Age | Since |
|---|---|---|---|
Donal O'Connor
BRD | Director/Board Member | 75 | 2014-10-31 |
Geoffrey Parker
BRD | Director/Board Member | 61 | 2016-11-06 |
Bradley Alford
BRD | Director/Board Member | 70 | 2017-02-05 |
Orlando Ashford
CHM | Chairman | 57 | - |
Albert Manzone
BRD | Director/Board Member | 63 | 2022-07-29 |
Julia Brown
BRD | Director/Board Member | 56 | 2023-10-31 |
Jonas Samuelson
BRD | Director/Board Member | 58 | 2025-01-14 |
Kevin Egan
BRD | Director/Board Member | 60 | 2025-04-30 |
A. Amin
BRD | Director/Board Member | 66 | 2026-06-29 |
Mohammad Gajial
BRD | Director/Board Member | 52 | 2026-06-29 |
Company details: Perrigo Company plc
Group companies: Perrigo Company plc
| Name | Category and Sector |
|---|---|
Galpharm International Ltd.
 Galpharm International Ltd. Pharmaceuticals: MajorHealth Technology Manufactures and supplies over-the-counter and branded medicines |
Pharmaceuticals: Major
|
Perrigo UK Acquisition Ltd.
 Perrigo UK Acquisition Ltd. Miscellaneous Commercial ServicesCommercial Services Provides business support services |
Miscellaneous Commercial Services
|
Wrafton Laboratories Ltd.
 Wrafton Laboratories Ltd. Pharmaceuticals: OtherHealth Technology Manufactures pharmaceutical products |
Pharmaceuticals: Other
|
Pharmaceuticals: Major
| |
Perrigo Capital NV
 Perrigo Capital NV Financial ConglomeratesFinance Functions as an investment holding company |
Financial Conglomerates
|
Other Pharmaceuticals
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.62% | +2.55% | +49.97% | +100.29% | 1,027B | |
| +0.20% | +1.85% | +55.32% | +66.49% | 651B | |
| +0.12% | +2.78% | +19.04% | +71.66% | 467B | |
| -1.22% | +3.66% | +36.44% | +38.32% | 350B | |
| -0.79% | +2.73% | +19.03% | +25.08% | 268B | |
| +0.58% | +6.76% | +11.13% | +16.52% | 257B | |
| +0.86% | +1.48% | +38.83% | +45.52% | 205B | |
| +0.79% | +1.84% | -28.27% | -56.71% | 190B | |
| +0.07% | +5.01% | +32.83% | +99.58% | 187B | |
| Average | -0.04% | +2.49% | +26.04% | +45.19% | 400.23B | |
| Weighted average by Cap. | -0.19% | +2.62% | +34.90% | +61.45% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
